Podcasts about targeted

he incomparable Queen of Punk's latest release, “Rollerdome” released this month, is an infectiously raucous anthem in waiting. She's headlining Calgary's The Rec Room on August 11. Bif Naked is also going before the cameras in a new documentary on her life and career from the co-director of “The Corporation,” for “Bif Naked: One of a Kind,” which will air on Super Channel as part of its original selections in early 2024. Bif Naked embodies the phrase “lived to tell the tale” and makes for a fascinating interview: orphaned, empowered, and inspired are just some of the reasons… Read below to see why Bif Naked transcended adversity to become one of the world's most unique, creative and adored icons. And of course, she is one of the nicest, kindest people you'll ever meet, and the author of the best-selling memoir about life, love, loss and triumph, I, Bificus. Bif Naked was born in secret to a teenager living in India, the product of a Canadian girl and a British boy. She was rejected by both families, hidden away in a mental hospital and adopted by missionaries and then moved to North America. She began what she recalls with ironic humour as a “charmed life.” Targeted by girl gangs and facing other abusive situations, she escaped this early life by joining a punk rock band and leaving on tour, where she married the drummer and hit a downward spiral that found her on the floor of a Vancouver drug den. Through it all, her creative personality and unstoppable humour were her weapons of self-defence. Bif showcased her life's journey in tattoo ink across her body and, with her unique ability to transform her true-life stories into song lyrics, she found her voice as a solo artist, started her own record company and at twenty-three years of age became an international recording artist. Throughout her remarkable career, armed with her singular talent and instantly identifiable look, Bif would captivate the imagination of audiences and media alike, releasing nine albums and twenty-one videos. She embarked on seemingly endless international tours, several feature films and multiple television roles, only to be struck down with breast cancer at the age of 37. Bif would discover her passion for advocacy, as a triumphant survivor and someone who helps others first. This is Bif Naked's story so far. *************************************************** Purchase Tickets For Thursdays Show in Calgary: https://www.therecroom.com/calgary-deerfoot/events/bif-naked/238298 Purchase Tickets for Friday's Show in Regina: https://theexchangelive.ca/event-calendar/post/bifnaked2022 *************************************************** Follow the Cross Border Interview Podcast: Instagram: https://www.instagram.com/crossborderpodcast/ Twitter: https://twitter.com/CrossBorderPod Facebook : https://www.facebook.com/CrossBorderInterviews Youtube: https://www.youtube.com/channel/UCI2i25ZVKTO84oUsLyO4jig Website: https://www.crossborderinterviews.ca/ Back the Show: https://www.patreon.com/CrossBoderInterviewPodcast The Cross Border Interview Podcast was Produced and Edited by Miranda, Brown & Associates Inc © 2022

--many layers to the story I'm about to dive into here on the Zeph Report. Many they will not tell you.

Go online to PeerView.com/ZBX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Treatment advances in metastatic melanoma have been characterized by the use of immunotherapy, including PD-1 and CTLA-4 checkpoint inhibitors, as well as targeted agents in BRAF-mutated disease—and collectively these modalities represent the driving forces leading to improved clinical outcomes across disease settings. How will new evidence change this current paradigm? In this MasterClass & Case Forum video activity, based on a live event at the 2022 ASCO Annual Meeting, an expert panel explores the latest practice-changing clinical evidence for managing BRAF-mutated melanoma, while providing case-based practical guidance on modern treatment decisions with immunotherapy and targeted agents. Learn how these experts are using novel immune-based options in this setting to improve outcomes for their patients with BRAF-mutated disease. Upon completion of this activity, participants should be better able to: Cite current evidence on the efficacy of modern sequential approaches to using immunotherapy and targeted regimens in the setting of BRAF-mutated, metastatic melanoma; Utilize optimized strategies with immunotherapy components for the initial and sequential management of patients with BRAF-mutated, metastatic melanoma; and Develop team-based, collaborative strategies for managing toxicity associated with the sequential use of immunotherapy and targeted agents in patients with metastatic melanoma.

Go online to PeerView.com/ZBX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Treatment advances in metastatic melanoma have been characterized by the use of immunotherapy, including PD-1 and CTLA-4 checkpoint inhibitors, as well as targeted agents in BRAF-mutated disease—and collectively these modalities represent the driving forces leading to improved clinical outcomes across disease settings. How will new evidence change this current paradigm? In this MasterClass & Case Forum video activity, based on a live event at the 2022 ASCO Annual Meeting, an expert panel explores the latest practice-changing clinical evidence for managing BRAF-mutated melanoma, while providing case-based practical guidance on modern treatment decisions with immunotherapy and targeted agents. Learn how these experts are using novel immune-based options in this setting to improve outcomes for their patients with BRAF-mutated disease. Upon completion of this activity, participants should be better able to: Cite current evidence on the efficacy of modern sequential approaches to using immunotherapy and targeted regimens in the setting of BRAF-mutated, metastatic melanoma; Utilize optimized strategies with immunotherapy components for the initial and sequential management of patients with BRAF-mutated, metastatic melanoma; and Develop team-based, collaborative strategies for managing toxicity associated with the sequential use of immunotherapy and targeted agents in patients with metastatic melanoma.

Fox News Radio's Tonya J. Powers gives us input on the Brittney Griner case, her sentencing and her conviction.  (Photo by Ethan Miller/Getty Images)

Go online to PeerView.com/ZBX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Treatment advances in metastatic melanoma have been characterized by the use of immunotherapy, including PD-1 and CTLA-4 checkpoint inhibitors, as well as targeted agents in BRAF-mutated disease—and collectively these modalities represent the driving forces leading to improved clinical outcomes across disease settings. How will new evidence change this current paradigm? In this MasterClass & Case Forum video activity, based on a live event at the 2022 ASCO Annual Meeting, an expert panel explores the latest practice-changing clinical evidence for managing BRAF-mutated melanoma, while providing case-based practical guidance on modern treatment decisions with immunotherapy and targeted agents. Learn how these experts are using novel immune-based options in this setting to improve outcomes for their patients with BRAF-mutated disease. Upon completion of this activity, participants should be better able to: Cite current evidence on the efficacy of modern sequential approaches to using immunotherapy and targeted regimens in the setting of BRAF-mutated, metastatic melanoma; Utilize optimized strategies with immunotherapy components for the initial and sequential management of patients with BRAF-mutated, metastatic melanoma; and Develop team-based, collaborative strategies for managing toxicity associated with the sequential use of immunotherapy and targeted agents in patients with metastatic melanoma.

Go online to PeerView.com/ZBX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Treatment advances in metastatic melanoma have been characterized by the use of immunotherapy, including PD-1 and CTLA-4 checkpoint inhibitors, as well as targeted agents in BRAF-mutated disease—and collectively these modalities represent the driving forces leading to improved clinical outcomes across disease settings. How will new evidence change this current paradigm? In this MasterClass & Case Forum video activity, based on a live event at the 2022 ASCO Annual Meeting, an expert panel explores the latest practice-changing clinical evidence for managing BRAF-mutated melanoma, while providing case-based practical guidance on modern treatment decisions with immunotherapy and targeted agents. Learn how these experts are using novel immune-based options in this setting to improve outcomes for their patients with BRAF-mutated disease. Upon completion of this activity, participants should be better able to: Cite current evidence on the efficacy of modern sequential approaches to using immunotherapy and targeted regimens in the setting of BRAF-mutated, metastatic melanoma; Utilize optimized strategies with immunotherapy components for the initial and sequential management of patients with BRAF-mutated, metastatic melanoma; and Develop team-based, collaborative strategies for managing toxicity associated with the sequential use of immunotherapy and targeted agents in patients with metastatic melanoma.

Go online to PeerView.com/ZBX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Treatment advances in metastatic melanoma have been characterized by the use of immunotherapy, including PD-1 and CTLA-4 checkpoint inhibitors, as well as targeted agents in BRAF-mutated disease—and collectively these modalities represent the driving forces leading to improved clinical outcomes across disease settings. How will new evidence change this current paradigm? In this MasterClass & Case Forum video activity, based on a live event at the 2022 ASCO Annual Meeting, an expert panel explores the latest practice-changing clinical evidence for managing BRAF-mutated melanoma, while providing case-based practical guidance on modern treatment decisions with immunotherapy and targeted agents. Learn how these experts are using novel immune-based options in this setting to improve outcomes for their patients with BRAF-mutated disease. Upon completion of this activity, participants should be better able to: Cite current evidence on the efficacy of modern sequential approaches to using immunotherapy and targeted regimens in the setting of BRAF-mutated, metastatic melanoma; Utilize optimized strategies with immunotherapy components for the initial and sequential management of patients with BRAF-mutated, metastatic melanoma; and Develop team-based, collaborative strategies for managing toxicity associated with the sequential use of immunotherapy and targeted agents in patients with metastatic melanoma.

Go online to PeerView.com/ZBX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Treatment advances in metastatic melanoma have been characterized by the use of immunotherapy, including PD-1 and CTLA-4 checkpoint inhibitors, as well as targeted agents in BRAF-mutated disease—and collectively these modalities represent the driving forces leading to improved clinical outcomes across disease settings. How will new evidence change this current paradigm? In this MasterClass & Case Forum video activity, based on a live event at the 2022 ASCO Annual Meeting, an expert panel explores the latest practice-changing clinical evidence for managing BRAF-mutated melanoma, while providing case-based practical guidance on modern treatment decisions with immunotherapy and targeted agents. Learn how these experts are using novel immune-based options in this setting to improve outcomes for their patients with BRAF-mutated disease. Upon completion of this activity, participants should be better able to: Cite current evidence on the efficacy of modern sequential approaches to using immunotherapy and targeted regimens in the setting of BRAF-mutated, metastatic melanoma; Utilize optimized strategies with immunotherapy components for the initial and sequential management of patients with BRAF-mutated, metastatic melanoma; and Develop team-based, collaborative strategies for managing toxicity associated with the sequential use of immunotherapy and targeted agents in patients with metastatic melanoma.

Go online to PeerView.com/ZBX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Treatment advances in metastatic melanoma have been characterized by the use of immunotherapy, including PD-1 and CTLA-4 checkpoint inhibitors, as well as targeted agents in BRAF-mutated disease—and collectively these modalities represent the driving forces leading to improved clinical outcomes across disease settings. How will new evidence change this current paradigm? In this MasterClass & Case Forum video activity, based on a live event at the 2022 ASCO Annual Meeting, an expert panel explores the latest practice-changing clinical evidence for managing BRAF-mutated melanoma, while providing case-based practical guidance on modern treatment decisions with immunotherapy and targeted agents. Learn how these experts are using novel immune-based options in this setting to improve outcomes for their patients with BRAF-mutated disease. Upon completion of this activity, participants should be better able to: Cite current evidence on the efficacy of modern sequential approaches to using immunotherapy and targeted regimens in the setting of BRAF-mutated, metastatic melanoma; Utilize optimized strategies with immunotherapy components for the initial and sequential management of patients with BRAF-mutated, metastatic melanoma; and Develop team-based, collaborative strategies for managing toxicity associated with the sequential use of immunotherapy and targeted agents in patients with metastatic melanoma.

Go online to PeerView.com/ZBX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Treatment advances in metastatic melanoma have been characterized by the use of immunotherapy, including PD-1 and CTLA-4 checkpoint inhibitors, as well as targeted agents in BRAF-mutated disease—and collectively these modalities represent the driving forces leading to improved clinical outcomes across disease settings. How will new evidence change this current paradigm? In this MasterClass & Case Forum video activity, based on a live event at the 2022 ASCO Annual Meeting, an expert panel explores the latest practice-changing clinical evidence for managing BRAF-mutated melanoma, while providing case-based practical guidance on modern treatment decisions with immunotherapy and targeted agents. Learn how these experts are using novel immune-based options in this setting to improve outcomes for their patients with BRAF-mutated disease. Upon completion of this activity, participants should be better able to: Cite current evidence on the efficacy of modern sequential approaches to using immunotherapy and targeted regimens in the setting of BRAF-mutated, metastatic melanoma; Utilize optimized strategies with immunotherapy components for the initial and sequential management of patients with BRAF-mutated, metastatic melanoma; and Develop team-based, collaborative strategies for managing toxicity associated with the sequential use of immunotherapy and targeted agents in patients with metastatic melanoma.

It appears the grudge between Dustin Poirier and Michael Chandler will be settled by the end of the year, much to the delight of UFC fans. On an all-new edition of Heck of a Morning, MMA Fighting's Mike Heck reacts to the targeted lightweight booking and where it currently stands. In addition, listener topics include UFC 279, A.J. McKee making the move to 155 pounds at Bellator 286 against Spike Carlyle and not fighting Patricio Pitbull in the trilogy fight for the featherweight title in October, fighter pay, the stacked UFC 280 card, The Ultimate Fighter and the lack of interest amongst fans, and more. Also, welterweight Billy Goff (34:22) joins the show to recap his stoppage win on Dana White's Contender Series on Tuesday to earn a UFC contract, talks who didn't deserve a contract on the card, when he'd like to make his octagon debut, and more. You can listen live to Heck of a Morning Tuesdays, Thursdays, and Fridays at 10 a.m. ET on the MMA Fighting Twitter Spaces. Follow Mike Heck: @MikeHeck_JR Subscribe: http://goo.gl/dYpsgH Check out our full video catalog: http://goo.gl/u8VvLi Visit our playlists: http://goo.gl/eFhsvM Like MMAF on Facebook: http://goo.gl/uhdg7Z Follow on Twitter: http://goo.gl/nOATUI Read More: http://www.mmafighting.com Learn more about your ad choices. Visit podcastchoices.com/adchoices

It appears the grudge between Dustin Poirier and Michael Chandler will be settled by the end of the year, much to the delight of UFC fans. On an all-new edition of Heck of a Morning, MMA Fighting's Mike Heck reacts to the targeted lightweight booking and where it currently stands. In addition, listener topics include UFC 279, A.J. McKee making the move to 155 pounds at Bellator 286 against Spike Carlyle and not fighting Patricio Pitbull in the trilogy fight for the featherweight title in October, fighter pay, the stacked UFC 280 card, The Ultimate Fighter and the lack of interest amongst fans, and more. Also, welterweight Billy Goff (34:22) joins the show to recap his stoppage win on Dana White's Contender Series on Tuesday to earn a UFC contract, talks who didn't deserve a contract on the card, when he'd like to make his octagon debut, and more. You can listen live to Heck of a Morning Tuesdays, Thursdays, and Fridays at 10 a.m. ET on the MMA Fighting Twitter Spaces. Follow Mike Heck: @MikeHeck_JR Subscribe: http://goo.gl/dYpsgH Check out our full video catalog: http://goo.gl/u8VvLi Visit our playlists: http://goo.gl/eFhsvM Like MMAF on Facebook: http://goo.gl/uhdg7Z Follow on Twitter: http://goo.gl/nOATUI Read More: http://www.mmafighting.com Learn more about your ad choices. Visit podcastchoices.com/adchoices

One serious challenge in the overall management of Fatty Liver disease involves creating cost-effective methods for "early" diagnosis. The term "early" is relative because, as Ian Rowe puts it, a "substantial proportion" of people admitted to hospital with various symptoms of decompensating cirrhosis or hepatic encephalopathy never received a diagnosis of advanced liver disease before they presented. Simply diagnosing these patients during advanced fibrosis (F2 or F3) can save lives, improve longevity and quality of life for these patients and save money for healthcare systems, all at the same time. Ian spends the first ten minutes of this episode describing a model he and Richard Parker developed to evaluate five diagnostic strategies:Targeted -- simple non-invasive liver screening Targeted + risk stratification -- targeted assessment plus FIB-4 or VCTE (FibroScan) for patients believed to be at high riskiLFT -- automated assessment of abnormal LFTs analyzed with other systemic measures in a medical record system "Comprehensive" -- a "kitchen sink" approach that runs iLFT analysis and conducts FIB-4 +/- VCTE on every patient"Fibrosis first" -- an approach that deploys viroserological and iron testing plus FIB-4 +/- VCTE for every patient "Fibrosis first" scored best in cost effectiveness (cost per correct diagnosis of treatable liver disease) and "decision curve analysis", which looks at true positive outcomes and false positive outcomes, correctly identifying 85% of treatable liver disease patients (vs. 90% for the comprehensive approach and less than 15% for the current targeted approach.)  Fibrosis first has the added benefit of not progressing treatment for people who may have steatosis without fibrosis. The rest of the conversation entails Ian, Louise Campbell and Roger Green sharing questions and observations. Highlights:Louise agrees that the current targeted pathway approaches do not work and  identifies lack of access to advanced testing in primary care as a central issue. She asks how many additional patients with Type 2 Diabetes, other metabolic diseases or CVD could be identified through this approach. Ian cannot answer because the question is outside the scope of the research. He points out that to assess different approaches accurately, researchers and policymakers need to settle on whether the goal is to identify steatohepatitis or something broader. Louise asks about the frequency and nature of referrals. Ian notes that one issue with iLFT is a high level of referrals for conditions that might not require treatment, the most common of which is "abnormal LFT without fibrosis."Roger notes that iLFT might help patients who complain they never heard about their NASH earlier. He also recalls Quentin Anstee and Stephen Harrison discussing recently that FIB-4 can serve as a prognostic measure not only for liver-related deaths, but also CV deaths and all-cause mortality. Louise suggests that patients will do better if they adopt a  behavior belief model instead of a sick patient approach and that the earlier in disease we intervene, the more success we will have. Roger and Ian note that Louise's focus is broader in scope than his model. Ian further notes that we do not know when non-fibrotic patients should be tested again, although he has some thoughts about this. Louise notes that one element that might make iLFT costly is that only 45% of patients picked up on iLFT are referred into the model. Ian notes that this insight might require changes in the model.As the conversation winds down, it shifts toward policy issues: should we focus testing on the workforce (Louise) and it the best point of intervention to limit advertising of unhealthy foods (Ian). 

It appears the grudge between Dustin Poirier and Michael Chandler will be settled by the end of the year, much to the delight of UFC fans. On an all-new edition of Heck of a Morning, MMA Fighting's Mike Heck reacts to the targeted lightweight booking and where it currently stands. In addition, listener topics include UFC 279, A.J. McKee making the move to 155 pounds at Bellator 286 against Spike Carlyle and not fighting Patricio Pitbull in the trilogy fight for the featherweight title in October, fighter pay, the stacked UFC 280 card, The Ultimate Fighter and the lack of interest amongst fans, and more. Also, welterweight Billy Goff (34:22) joins the show to recap his stoppage win on Dana White's Contender Series on Tuesday to earn a UFC contract, talks who didn't deserve a contract on the card, when he'd like to make his octagon debut, and more. You can listen live to Heck of a Morning Tuesdays, Thursdays, and Fridays at 10 a.m. ET on the MMA Fighting Twitter Spaces. Follow Mike Heck: @MikeHeck_JR Subscribe: http://goo.gl/dYpsgH Check out our full video catalog: http://goo.gl/u8VvLi Visit our playlists: http://goo.gl/eFhsvM Like MMAF on Facebook: http://goo.gl/uhdg7Z Follow on Twitter: http://goo.gl/nOATUI Read More: http://www.mmafighting.com Learn more about your ad choices. Visit podcastchoices.com/adchoices

With BTC and ETH trading in the green despite network hacks on the Solana blockchain, plus a look at how big crypto stadium sponsorships work, CoinDesk's “Markets Daily” is back with the latest news roundup. This episode is sponsored by Algorand.Today's Stories...Read the full show notes here.Featured Story: Crypto.com and FTX Bet Big on Stadium Naming Rights Before the Crypto Crash. What Happens if They Can't Afford to Pay?-Algorand is shaping the future with the world's greenest blockchain technology. Algorand delivers security, scalability, and speed without sacrifice – inspiring you and billions of other users to reach a sustainable standard of peak blockchain performance. Learn more at algorand.foundation. -This episode was edited & produced by Adrian Blust with original music by Doc Blust & Colin Mealey.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Chinese fighter jets and warships circle Taiwan as House Speaker Nancy Pelosi visits the island. Plus, new images and details of Ayman al-Zawahiri's hideout, the al Qaeda leader who was recently killed by a U.S. drone strike. Then, it is election night in America as voters cast their ballots in five key states.To learn more about how CNN protects listener privacy, visit cnn.com/privacy

Go online to PeerView.com/JJJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you ready to make personalized treatment choices with the potent suite of targeted agents, including BTK and BCL-2 inhibitors, that have become standards of care in chronic lymphocytic leukemia (CLL)? In collaboration with the CLL Society, this PeerView MasterClass & Case Forum, based on a live event at the ASCO Annual Meeting, will give learners foundational insights on the evidence that supports the use of personalized therapy with modern targeted platforms. Watch the expert panel present a series of highly practical case discussions that include guidance on: the evidence-based selection of treatment strategies for treatment-naïve and relapsed CLL; therapeutic planning based on safety considerations; and the integration of novel combinatorial and cellular therapy strategies. Don't miss this expert-led program and receive CME/MOC credit! Upon completion of this activity, participants should be better able to: Summarize updated efficacy and safety evidence supporting the integration of novel therapeutic classes in CLL, including evidence with BTK, PI3K, and BCL-2 inhibitors, novel combinations, and CAR-T options; Recommend personalized treatment with targeted agents, including fixed duration or continuous therapy strategies or appropriate combinatorial or sequential options, for patients presenting with treatment-naïve or relapsed/refractory CLL; and Manage unique safety considerations associated with the use of targeted agents, novel antibodies, or cellular therapies in the CLL setting.

The U.S. kills Al Qaeda leader Ayman al-Zawahiri in a precise drone missile strike as he hid in plain sight in a Kabul safe house. President Biden examined a scale model of Zawahiri's home as he weighed taking out the world's most wanted terrorist to minimize civilian casualties. Don and the panel discuss the painstaking process of intelligence gathering that took place without having boots on the ground, and what this victory means for the Biden Administration one year since the chaotic U.S. military withdrawal from Afghanistan.Plus, key House Democrats renew calls for the DHS Investigator General to step aside from the probe into the missing January 6 texts, NBA hall of famer and civil rights activist Bill Russell dies at 88, and tensions flare between the U.S. and China ahead of House Speaker Nancy Pelosi's expected visit to Taiwan.To learn more about how CNN protects listener privacy, visit cnn.com/privacy

Zero To Diamond is a social media platform and free coaching program for real estate agents Mission statement: To reduce the failure rate in the real estate industry one agent at a time 1,000's of agents worldwide have doubled and tripled their business I am here to help you so DM on IG anytime: rickycarruth Join the movement: https://zerotodiamond.com

Go online to PeerView.com/JJJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you ready to make personalized treatment choices with the potent suite of targeted agents, including BTK and BCL-2 inhibitors, that have become standards of care in chronic lymphocytic leukemia (CLL)? In collaboration with the CLL Society, this PeerView MasterClass & Case Forum, based on a live event at the ASCO Annual Meeting, will give learners foundational insights on the evidence that supports the use of personalized therapy with modern targeted platforms. Watch the expert panel present a series of highly practical case discussions that include guidance on: the evidence-based selection of treatment strategies for treatment-naïve and relapsed CLL; therapeutic planning based on safety considerations; and the integration of novel combinatorial and cellular therapy strategies. Don't miss this expert-led program and receive CME/MOC credit! Upon completion of this activity, participants should be better able to: Summarize updated efficacy and safety evidence supporting the integration of novel therapeutic classes in CLL, including evidence with BTK, PI3K, and BCL-2 inhibitors, novel combinations, and CAR-T options; Recommend personalized treatment with targeted agents, including fixed duration or continuous therapy strategies or appropriate combinatorial or sequential options, for patients presenting with treatment-naïve or relapsed/refractory CLL; and Manage unique safety considerations associated with the use of targeted agents, novel antibodies, or cellular therapies in the CLL setting.

Go online to PeerView.com/JJJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you ready to make personalized treatment choices with the potent suite of targeted agents, including BTK and BCL-2 inhibitors, that have become standards of care in chronic lymphocytic leukemia (CLL)? In collaboration with the CLL Society, this PeerView MasterClass & Case Forum, based on a live event at the ASCO Annual Meeting, will give learners foundational insights on the evidence that supports the use of personalized therapy with modern targeted platforms. Watch the expert panel present a series of highly practical case discussions that include guidance on: the evidence-based selection of treatment strategies for treatment-naïve and relapsed CLL; therapeutic planning based on safety considerations; and the integration of novel combinatorial and cellular therapy strategies. Don't miss this expert-led program and receive CME/MOC credit! Upon completion of this activity, participants should be better able to: Summarize updated efficacy and safety evidence supporting the integration of novel therapeutic classes in CLL, including evidence with BTK, PI3K, and BCL-2 inhibitors, novel combinations, and CAR-T options; Recommend personalized treatment with targeted agents, including fixed duration or continuous therapy strategies or appropriate combinatorial or sequential options, for patients presenting with treatment-naïve or relapsed/refractory CLL; and Manage unique safety considerations associated with the use of targeted agents, novel antibodies, or cellular therapies in the CLL setting.

Jeannie Ridings, the attorney representing Corinna Sac, joins Lisa Dent on Chicago’s Afternoon News to explain why she feels Lake in The Hills officials were wrong to send a notice to stop hosting public events at her client’s bakery because of zoning issues following a hate crime last month after planning a family-friendly drag show. […]

Go online to PeerView.com/JJJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you ready to make personalized treatment choices with the potent suite of targeted agents, including BTK and BCL-2 inhibitors, that have become standards of care in chronic lymphocytic leukemia (CLL)? In collaboration with the CLL Society, this PeerView MasterClass & Case Forum, based on a live event at the ASCO Annual Meeting, will give learners foundational insights on the evidence that supports the use of personalized therapy with modern targeted platforms. Watch the expert panel present a series of highly practical case discussions that include guidance on: the evidence-based selection of treatment strategies for treatment-naïve and relapsed CLL; therapeutic planning based on safety considerations; and the integration of novel combinatorial and cellular therapy strategies. Don't miss this expert-led program and receive CME/MOC credit! Upon completion of this activity, participants should be better able to: Summarize updated efficacy and safety evidence supporting the integration of novel therapeutic classes in CLL, including evidence with BTK, PI3K, and BCL-2 inhibitors, novel combinations, and CAR-T options; Recommend personalized treatment with targeted agents, including fixed duration or continuous therapy strategies or appropriate combinatorial or sequential options, for patients presenting with treatment-naïve or relapsed/refractory CLL; and Manage unique safety considerations associated with the use of targeted agents, novel antibodies, or cellular therapies in the CLL setting.

Go online to PeerView.com/JJJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you ready to make personalized treatment choices with the potent suite of targeted agents, including BTK and BCL-2 inhibitors, that have become standards of care in chronic lymphocytic leukemia (CLL)? In collaboration with the CLL Society, this PeerView MasterClass & Case Forum, based on a live event at the ASCO Annual Meeting, will give learners foundational insights on the evidence that supports the use of personalized therapy with modern targeted platforms. Watch the expert panel present a series of highly practical case discussions that include guidance on: the evidence-based selection of treatment strategies for treatment-naïve and relapsed CLL; therapeutic planning based on safety considerations; and the integration of novel combinatorial and cellular therapy strategies. Don't miss this expert-led program and receive CME/MOC credit! Upon completion of this activity, participants should be better able to: Summarize updated efficacy and safety evidence supporting the integration of novel therapeutic classes in CLL, including evidence with BTK, PI3K, and BCL-2 inhibitors, novel combinations, and CAR-T options; Recommend personalized treatment with targeted agents, including fixed duration or continuous therapy strategies or appropriate combinatorial or sequential options, for patients presenting with treatment-naïve or relapsed/refractory CLL; and Manage unique safety considerations associated with the use of targeted agents, novel antibodies, or cellular therapies in the CLL setting.

Go online to PeerView.com/JJJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you ready to make personalized treatment choices with the potent suite of targeted agents, including BTK and BCL-2 inhibitors, that have become standards of care in chronic lymphocytic leukemia (CLL)? In collaboration with the CLL Society, this PeerView MasterClass & Case Forum, based on a live event at the ASCO Annual Meeting, will give learners foundational insights on the evidence that supports the use of personalized therapy with modern targeted platforms. Watch the expert panel present a series of highly practical case discussions that include guidance on: the evidence-based selection of treatment strategies for treatment-naïve and relapsed CLL; therapeutic planning based on safety considerations; and the integration of novel combinatorial and cellular therapy strategies. Don't miss this expert-led program and receive CME/MOC credit! Upon completion of this activity, participants should be better able to: Summarize updated efficacy and safety evidence supporting the integration of novel therapeutic classes in CLL, including evidence with BTK, PI3K, and BCL-2 inhibitors, novel combinations, and CAR-T options; Recommend personalized treatment with targeted agents, including fixed duration or continuous therapy strategies or appropriate combinatorial or sequential options, for patients presenting with treatment-naïve or relapsed/refractory CLL; and Manage unique safety considerations associated with the use of targeted agents, novel antibodies, or cellular therapies in the CLL setting.

Go online to PeerView.com/JJJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you ready to make personalized treatment choices with the potent suite of targeted agents, including BTK and BCL-2 inhibitors, that have become standards of care in chronic lymphocytic leukemia (CLL)? In collaboration with the CLL Society, this PeerView MasterClass & Case Forum, based on a live event at the ASCO Annual Meeting, will give learners foundational insights on the evidence that supports the use of personalized therapy with modern targeted platforms. Watch the expert panel present a series of highly practical case discussions that include guidance on: the evidence-based selection of treatment strategies for treatment-naïve and relapsed CLL; therapeutic planning based on safety considerations; and the integration of novel combinatorial and cellular therapy strategies. Don't miss this expert-led program and receive CME/MOC credit! Upon completion of this activity, participants should be better able to: Summarize updated efficacy and safety evidence supporting the integration of novel therapeutic classes in CLL, including evidence with BTK, PI3K, and BCL-2 inhibitors, novel combinations, and CAR-T options; Recommend personalized treatment with targeted agents, including fixed duration or continuous therapy strategies or appropriate combinatorial or sequential options, for patients presenting with treatment-naïve or relapsed/refractory CLL; and Manage unique safety considerations associated with the use of targeted agents, novel antibodies, or cellular therapies in the CLL setting.

Go online to PeerView.com/JJJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you ready to make personalized treatment choices with the potent suite of targeted agents, including BTK and BCL-2 inhibitors, that have become standards of care in chronic lymphocytic leukemia (CLL)? In collaboration with the CLL Society, this PeerView MasterClass & Case Forum, based on a live event at the ASCO Annual Meeting, will give learners foundational insights on the evidence that supports the use of personalized therapy with modern targeted platforms. Watch the expert panel present a series of highly practical case discussions that include guidance on: the evidence-based selection of treatment strategies for treatment-naïve and relapsed CLL; therapeutic planning based on safety considerations; and the integration of novel combinatorial and cellular therapy strategies. Don't miss this expert-led program and receive CME/MOC credit! Upon completion of this activity, participants should be better able to: Summarize updated efficacy and safety evidence supporting the integration of novel therapeutic classes in CLL, including evidence with BTK, PI3K, and BCL-2 inhibitors, novel combinations, and CAR-T options; Recommend personalized treatment with targeted agents, including fixed duration or continuous therapy strategies or appropriate combinatorial or sequential options, for patients presenting with treatment-naïve or relapsed/refractory CLL; and Manage unique safety considerations associated with the use of targeted agents, novel antibodies, or cellular therapies in the CLL setting.

The Filtrate:Joel TopfSwapnil HiremathJosh WaitzmanJordy CohenSpecial Guest:Sean Barbour. Clinical Associate Professor, Division of Nephrology, University of British Columbia Chair, BC Glomerulonephritis Committee and Network, BC RenalEditor:Joel TopfShow Notes:NephJC Summary of TESTING: Re-TESTING Steroids for IgA Nephropathy (have you ever noticed how good the titles for the NephJC summaries are?)TESTING in JAMASTOP-IgA NephJC Summary: Don't just do something, stand there. Another great title, this one from from a long time ago.The British Columbia GN network really owes its existence to TESTING: An overview of the British Columbia Glomerulonephritis network and registry: integrating knowledge generation and translation within a single framework (PubMed)Dunning–Kruger effect WikipediaPrior Art for steroids in IgA nephropathy:Italian study: Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathyAnother, earlier, Italian study: Corticosteroids in IgA nephropathy: a randomised controlled trialChinese study: Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: a randomized controlled trialOriginal TESTING publication from 2017, also in JAMA. Oh, and we covered that in NephJC too, IgA Nephropathy: Testing Steroids Again.NephJC also talked about Sean Barbour's risk score for IgA Nephropathy: Summary | Freely Filtered Podcast episode 5A Controlled Trial of Fish Oil in IgA Nephropathy in the NEJM!Stevens-Johnson Syndrome. “When to see a doctor Stevens-Johnson syndrome requires immediate medical attention. Seek emergency medical care if you experience signs and symptoms of this condition.” Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency (PubMed)Adaptive Trials in NephMadness 2016 with Selection Committee Member, Perry Wilson!TreifGeographic Differences in Genetic Susceptibility to IgA Nephropathy: GWAS Replication Study and Geospatial Risk AnalysisThe MEST score provides earlier risk prediction in lgA nephropathyDAPA-IgA: A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathySwap and Josh fight about SGLT2i in IgA NephropathySignificance of serum galactose deficient IgA1 as a potential biomarker for IgA nephropathy: A case control study (PubMed)FDA approves first drug to decrease urine protein in IgA nephropathy, a rare kidney disease. FDA has granted accelerated approval for  budesonide delayed release capsules to reduce proteinuria in adults with primary IgA nephropathy at risk of rapid disease progression. It has not been established whether budesonide delayed release capsules slow kidney function decline in patients with IgA nephropathy. Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial (Lancet)Omicron in Ontario.Prescribing Nirmatrelvir/Ritonavir for COVID-19 in Advanced CKD by SwapStar Trek: Strange New WorldsOrigins of Renal Physiology: Fellows 2022 Medical Students: Kidney TREKSApplication of the International IgA Nephropathy Prediction Tool one or two years post-biopsy (Kidney International)The Triple Crown in Virginia

We discuss the latest surrounding the Knicks and 76ers who are both being investigated by the NBA for their actions this offseason, the Heat's rumored pursuit of Hawks big man John Collins, Russell Westbrook changing agents plus the passing of Bill Russell... Learn more about your ad choices. Visit podcastchoices.com/adchoices

Longtime family friend of Jared from Jared and Katie in the Morning, Jared Bridegan was murdered 6 months ago in front of his 2 year old daughter in what authorities are calling a targeted attack.   Kirsten Bridegan (widow) joins Jared and Katie in the Morning to share what happened on that day Jared Bridegan was tragically murdered and the latest in the investigation.   If you have any info contact law enforcement or send info to JusticeForJaredB on IG.See omnystudio.com/listener for privacy information.

Erwin McManus takes us on a journey through his Quest for Enlightenment in his powerful Uprising series. Targeted on the value of wisdom, Pastor Erwin shares that for most of us, the wisest person in our life is not the wealthiest or the smartest. What they bring is an ability to navigate life in a way that leads to wholeness - both emotionally and relationally. In Ecclesiastes chapter 9, a man named Solomon points out a man who was poor but saved a city with his wisdom. Pastor Erwin reminds us that we often ask for resources when God wants to give us vision. What vision has God entrusted you with that you need his wisdom to navigate? Even when your resources cause you to second guess what you can achieve, this message will encourage you to trust that God's supply of wisdom is more than enough! This message is drawn from Uprising, Erwin Raphael McManus' book about taking on the character of God.

Longtime family friend of Jared from Jared and Katie in the Morning, Jared Bridegan was murdered 6 months ago in front of his 2 year old daughter in what authorities are calling a targeted attack.   Kirsten Bridegan (widow) joins Jared and Katie in the Morning to share what happened on that day Jared Bridegan was tragically murdered and the latest in the investigation.   If you have any info contact law enforcement or send info to JusticeForJaredB on IG.See omnystudio.com/listener for privacy information.

CHEST August 2022, Volume 162, Issue 2 Jean-Baptiste Lascarrou, MD, and Markus B Skrifvars, MD, PhD, join CHEST Podcast Moderator, Dominique Pepper, MD, to discuss targeted temperature management after in-hospital cardiac arrest. DOI: https://doi.org/10.1016/j.chest.2022.02.056

Do you want to grow your business and drive more customers with the most effective content marketing? Call Media Plan (+64-21-177-3001) for bespoke visibility campaigns! Learn more at: https://www.mediaplan.co.nz (https://www.mediaplan.co.nz)

Calls for a more targeted approach to tackle the cost of living crisis. On Monday, the Government makes the first of three $116 payments to those earning less than $70,000. It was the flagship announcement in the Budget, designed to help Kiwis hit hardest by the record-high cost of living. But financial adviser Liz Koh told Heather Du Plessis-Allan it should have been targeted to the poorest Kiwis. “We need to be helping people who are really at that end of the spectrum or they're struggling to just have a basic standard of living, and there's an increasing number of them.” LISTEN ABOVESee omnystudio.com/listener for privacy information.

A lawsuit against Instagram alleges the popular social media site is responsible for mental health issues and even suicide among teens. A mom of a three-year-old took down videos on TikTok of her toddler because they were being used by online predators. Are your kids being targeted on social media? The Rick Roberts Show is on NewsTalk 820 WBAP ... (Photo Courtesy of WFAA)See omnystudio.com/listener for privacy information.

Inflation continues and the Federal Reserve will probably raise interest rates again today so the Morning Show with Nikki Medoro speaks with ABC White House Correspondent Karen Travers to outline how the Biden Administration is trying to manage the economy. Also, ABC Senior Investigative Reporter Aaron Katersky talks about the House Committee grilling gun manufacturer CEOs today.See omnystudio.com/listener for privacy information.

Featuring perspectives from Dr Richard Stone, including the following topics: Introduction: RATIFY trial in perspective (0:00) Treatment with FLT3 inhibitors (7:00) Anti-CD47 antibody: Magrolimab (23:04) Anti-TIM-3 antibody: Sabatolimab (31:23) CAR T-cell therapy for acute myeloid leukemia (34:53) Targeted therapy with IDH inhibitors (37:31) New myelodysplastic syndromes classification system (41:20) Hypomethylating agents/venetoclax (45:11) CPX-351 (49:14) Other key data sets (50:59) CME information and select publications

The Justice Department has questioned former top advisers to Mike Pence over Donald Trump's effort to overturn the 2020 election results. Federal investigations hastened the retirement of WWE Chief Executive Vince McMahon, according to people familiar with the matter. Keith Collins hosts. Learn more about your ad choices. Visit megaphone.fm/adchoices

Today's guests: Admiral James Stavridis, Vice Chair, The Carlyle Group, author “To Risk It All”. Tevi Troy, Former United States Deputy Secretary of Health and Human Services. David Drucker, senior political correspondent, Washington Examiner and author, “In Trump's Shadow”. Byron York, chief political correspondent, Washington Examiner. Josh Kraushaar, political editor, National Journal. See omnystudio.com/listener for privacy information.

Preparation is the key to success, and also the key to a successful in-store event. Megan Crabtree has helped a number of jewelers take their in-store events from the $300,000 range to the $1m+ realm. Targeted advertising with big payoffs, arming your sales representatives with data and incentives, and most importantly, learning from what goes well and what doesn't. It's all part of Megan's playbook that continues to payoff for jewelers. Listen in and start your preparations today!Learn more about Crabtree Consulting: crabtreeadvisory.com

Jim Duffy is the President of The Litigation Connection. His business is finding the best litigation lawyers that fit his client's very particular needs and niche. He walks through his research process which has dramatically increased his bookings and how to utilize this research during the actual cold call. Jim emphasizes the need to be genuine in developing a relationship and determining fit, rather than being salesy, as there is simply no need for it in his space.  HIGHLIGHTS Getting in front of litigation lawyers and having more conversations Researching and creating a sub-persona beneath the persona within the ICP Cold call success: Research, a calm demeanor, and genuineness QUOTES Researching niche litigation lawyers Jim: "I look at different keywords and then we take those keywords and we'll look at the left of that phrase, left of that keyword and the right of that keyword and pull those phrases together, and that creates this phrase that really is the phrase that matters because it really tells about what they do vis-à-vis what my client does." Creating a story using talking points from outsourced research Jim: "As the phone's ringing, I'm looking at the notes I already have, he was... on the John Gotti trial, and then I'm looking all these other points, and then I'm scraping that also and putting in it as a tag. So it's almost like a story of all these disparate pieces of information and the person who's making the phone call has to have the ability to take those disparate points and put it into a sentence." Calm demeanor versus fast talking on a call cold Jim: "I'm not saying that somebody who's high energy can't be successful but I think that the person that's receiving a call or talking to somebody doesn't want to speak to a fast talker or the one that seems like the Diamond Jim. They want to talk to somebody who's genuine and having a calm demeanor and having a good conversation about what the situation is all about."  Find out more about Jim in the links below: LinkedIn: https://www.linkedin.com/in/jim-duffy-bb95576/ Twitter: https://mobile.twitter.com/socialseller1 Website (under construction): http://litigationconnection.com/ Phone: 708-629-9333 More on Andy: Connect on LinkedIn Get Andy's new book "Sell Without Selling Out" on Amazon Learn more at AndyPaul.com Sponsored by: Revenue.io | Unlock exponential growth with an AI-powered RevOps platform | Revenue.io Scratchpad | The fastest way to update Salesforce, take sales notes, and stay on top of to-dos | Scratchpad.com Blueboard | World's leading experiential rewards & recognition platform | Blueboard.com Explore the Revenue.io Podcast Universe: Sales Enablement Podcast RevOps Podcast Selling with Purpose Podcast

Michael Moore, the former United States Attorney for the Middle District of Georgia and a partner at Moore Hall, discusses the ramping up of the Fulton County District Attorney's investigation into criminal interference in the 2020 presidential election. Securities law expert James Cox, a Professor at Duke Law School, and Bloomberg Precious Metals Reporter Eddie Spence, discuss the trial of three former big hitters of the gold market at JP Morgan Chase for spoofing. June Grasso hosts. See omnystudio.com/listener for privacy information.

This is an urgent update episode with courageous mother and daughter of John Walsh, Meghan Walsh. Please listen - video is only 20 minutes long making it easy to listen to and easy to share. We will be doing a longer episode next week for all of you and in the meantime would appreciate everyone rising up and helping bring awareness to this curious case of an innocent mother who's 4 children were taken from her loving arms and put into the arms of John and Reve Walsh and into the CPS / Foster Care system. This is a crime against her and her children and MUST be exposed. Please listen and help resource Meghan and her team in their efforts to get her children back into her arms!DONATE TO MEGHAN: GiveSendGo: GiveSendGo - Save Meghan Walsh's Children: The #1 Free Christian Fundraising Site.Donate directly to the Zelle or office of Meghan's attorney, Hollis E Mandel: 954-791-1237Call Hollis: 954-791-1237Checks accepted by: The Law Office of Hollis E. Mandell LawPO Box 551600 Davie FL, 33355CONNECT WITH MEGHAN: Twitter: @MeghanWalsh - Meghan Walsh (@MeghanWalsh_) / Twitter Support the show

Nate Diaz wanted to get the last fight under his UFC contract on the books, and he looks to have gotten it in the main event of UFC 279 against Khamzat Chimaev. MMA Fighting's Mike Heck and Alexander K. Lee react to the booking, the fight being the main event of the card, if it will in fact be Diaz's final fight in the UFC, and more. Follow Mike Heck: @MikeHeck_JR Follow Alexander K. Lee: @AlexanderKLee Subscribe: http://goo.gl/dYpsgH Check out our full video catalog: http://goo.gl/u8VvLi Visit our playlists: http://goo.gl/eFhsvM Like MMAF on Facebook: http://goo.gl/uhdg7Z Follow on Twitter: http://goo.gl/nOATUI Read More: http://www.mmafighting.com Learn more about your ad choices. Visit podcastchoices.com/adchoices

Nate Diaz wanted to get the last fight under his UFC contract on the books, and he looks to have gotten it in the main event of UFC 279 against Khamzat Chimaev. MMA Fighting's Mike Heck and Alexander K. Lee react to the booking, the fight being the main event of the card, if it will in fact be Diaz's final fight in the UFC, and more. Follow Mike Heck: @MikeHeck_JR Follow Alexander K. Lee: @AlexanderKLee Subscribe: http://goo.gl/dYpsgH Check out our full video catalog: http://goo.gl/u8VvLi Visit our playlists: http://goo.gl/eFhsvM Like MMAF on Facebook: http://goo.gl/uhdg7Z Follow on Twitter: http://goo.gl/nOATUI Read More: http://www.mmafighting.com Learn more about your ad choices. Visit podcastchoices.com/adchoices

Steve Schneider objected to his school district showing obscene material and subjecting his 8 year old daughter to gender dysphoria without notification. He was subsequently targeted by the school district as well as police, who came and searched his home.  If you want to support the show, you can donate here: http://bit.ly/cd-donate Become a Conservative Daily member right now for massive savings on Faxblasts, discounts at Joe's Depot, and more perks like backstage time with the hosts of Conservative Daily! Use the link and sign up today! https://conservative-daily.com/forms/Step1b Make sure you Like, Comment, and Share! Text FREEDOM to 89517 to get added to our text list to receive notifications when we go Live! Please make sure you join our newsletter to receive our action alerts: https://bit.ly/joinconservativedaily Get you and your family prepared at the Brighteon Store right now and stock up on high quality storeable food, survival gear, and the cleanest supplements on the planet! https://bit.ly/3PezXDd Liberty Cigars is a Patriot owned business with an extensive line of historically themed individual cigars and cigar collections including the Commander Series, Founders Series, and the Presidents Series. All packaging is proudly made in the USA by American workers. A truly unique gift for both cigar and history lovers. All orders over $76 will receive a free Patrick Henry cigar, the perfect gift for anyone who says, "Give Me Liberty or Give Me Death" this holiday season. Use code REPUBLIC at www.libertycigars.com Go to IPVANISH.com/daily and use promotional code DAILY - and claim your 70% savings.  That's I-P-V-A-N-I-S-H.com/daily. Go to axosbank.com/daily and check out their rewards checking account! If you want to support Mike Lindell and our show, use promo code CD21 to get up to 66% off at https://www.mypillow.com/radiospecials or by placing your order over the phone at 800-872-0627. When you use promo code CD21, a Queen Sized MyPillow is just $29, the cheapest it has ever been! Conservative Daily is on Rumble! https://rumble.com/user/ConservativeDaily We are now also going to be streaming on dlive! Check us out here: https://dlive.tv/ConservativeDaily Click here to donate: http://bit.ly/cd-donate Subscribe to our daily podcast at Apple Podcasts: http://bit.ly/ConservativeDailyPodcast on Google Podcasts (for Android users): https://bit.ly/CDPodcastGoogle We are also available on Spotify! https://open.spotify.com/show/2wD8YleiBM8bu0l3ahBLDN And on Pandora: https://www.pandora.com/podcast/conservative-daily-podcast/PC:37034 And on iHeart Radio: https://www.iheart.com/podcast/256-conservative-daily-podcast-53710765/ on TuneIn: https://tunein.com/radio/Conservative-Daily-Podcast-p1350272/ And on Podbean: https://conservative.podbean.com/ And now also on Audible! https://www.audible.com/pd/Conservative-Daily-Podcast-Podcast/B08JJQQ4M Support Joe Oltmann in his legal battle against Eric Coomer: https://givesendgo.com/defendjoeoltmann